

October 16, 2023
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Onconova Therapeutics announces Encouraging Rigosertib Data
in RDEB-associated SCC Presented at EADV as Late Breaker**

TOKYO, Japan, October 16, 2023 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") today announced that its U.S. licensor for rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB), associated with advanced/metastatic squamous cell carcinoma (SCC), was presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) in Berlin, Germany, by Professor Dr. Johann Bauer, from the University Hospital Salzburg, Dermatology and Allergology of the PMU, on October 12, 2023.

Presentation Details

Date: Thursday, October 12, 2023

Abstract Title: Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) Associated Advanced/Metastatic Squamous Cell Carcinoma (SCC)

Presenter: Prof. Dr. Johann Bauer, M.D., MBA

Session: D2T01.3 Late breaking news

For Onconova's full press release, please visit Onconova's website: <https://investor.onconova.com/press-releases>

About rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for rigosertib from Onconova in July 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. For more information, please visit <https://www.onconova.com>

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, representative: Stephane Berthier).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.